(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of -91.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 10,214.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,467.21%.
Traws Pharma's revenue in 2025 is $2,846,000.On average, 3 Wall Street analysts forecast TRAW's revenue for 2025 to be $1,874,657, with the lowest TRAW revenue forecast at $1,801,141, and the highest TRAW revenue forecast at $1,929,794.
In 2026, TRAW is forecast to generate $2,445,205 in revenue, with the lowest revenue forecast at $2,349,315 and the highest revenue forecast at $2,517,123.